Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast Cancer
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Pembrolizumab|DRUG: Paclitaxel
Sponsor: Queen Mary University of London
Collaborators: Merck Sharp & Dohme LLC|European Institute of Oncology